Novo Holdings A/S
Novo Holdings A/S reported 27 holdings worth US$1.49B as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Novo Holdings A/S reported 27 holdings worth US$1.49B as of Sep 30, 2026. Largest: Edgewise Therapeutics, Inc., ASML Holding NV and Brookfield Corporation. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 27
- Value as reported
- US$1.49B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Edgewise Therapeutics, Inc. | 5.35M | US$217M | 14.6% |
| ASML Holding NV | 94,946 | US$172M | 11.5% |
| Brookfield Corporation | 4.47M | US$163M | 10.9% |
| Hemab Therapeutics Holdings, Inc. | 4.18M | US$129M | 8.7% |
| Avalyn Pharma Inc. | 3.45M | US$98.3M | 6.6% |
| Mirum Pharmaceuticals, Inc. | 1.13M | US$96.2M | 6.5% |
| Salesforce, Inc. | 393K | US$90.3M | 6.1% |
| Enliven Therapeutics, Inc. | 1M | US$45.8M | 3.1% |
| 4D Molecular Therapeutics, Inc. | 3M | US$42.9M | 2.9% |
| Obsidian Therapeutics, Inc. | 3.12M | US$42.9M | 2.9% |
| Vaxcyte, Inc. | 710K | US$40.4M | 2.7% |
| Floor & Decor Holdings, Inc. | 797K | US$36.5M | 2.5% |
| Viridian Therapeutics, Inc. | 1.75M | US$36M | 2.4% |
| ArriVent BioPharma, Inc. | 1.18M | US$35.6M | 2.4% |
| Insmed Incorporated | 284K | US$32.5M | 2.2% |
| Celldex Therapeutics, Inc. | 950K | US$30.8M | 2.1% |
| Alibaba Group Holding Limited | 257K | US$27.7M | 1.9% |
| Xenon Pharmaceuticals Inc. | 652K | US$24.3M | 1.6% |
| Scholar Rock Holding Corporation | 460K | US$22.2M | 1.5% |
| Dyne Therapeutics, Inc. | 1.38M | US$22.2M | 1.5% |
| MapLight Therapeutics, Inc. | 2.09M | US$21.3M | 1.4% |
| Contineum Therapeutics, Inc. | 704K | US$9.45M | 0.63% |
| Alumis Inc. | 1.25M | US$9.24M | 0.62% |
| BridgeBio Oncology Therapeutics, Inc. | 2.25M | US$9.22M | 0.62% |
| Marqeta, Inc. | 110K | US$1.88M | 0.13% |
| LanzaTech Global, Inc. | 158K | US$903K | 0.06% |
| Crinetics Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC
Related